



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Journal Pre-proof



High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya

Isaac Ngere MD , Jeanette Dawa PhD , Elizabeth Hunsperger PhD , Nancy Otieno MSc , Moses Masika MD , Patrick Amoth MD , Lyndah Makayotto MD , Carolyne Nasimiyu MD , Bronwyn M. Gunn PhD , Bryan Nyawanda MSc , Ouma Oluga MD , Carolyne Ngunu MD , Harriet Mirieri MPH , John Gachohi PhD , Doris Marwanga MSc , Patrick K. Munywoki PhD , Dennis Odhiambo BSc , Moshe D. Alando BSc , Robert F. Breiman MD , Omu Anzala PhD , M. Kariuki Njenga PhD , Marc Bulterys MD , Amy Herman-Roloff PhD , Eric Osoro MD

PII: S1201-9712(21)00696-2
DOI: <https://doi.org/10.1016/j.ijid.2021.08.062>
Reference: IJID 5674

To appear in: *International Journal of Infectious Diseases*

Received date: 15 May 2021
Revised date: 12 August 2021
Accepted date: 26 August 2021

Please cite this article as: Isaac Ngere MD , Jeanette Dawa PhD , Elizabeth Hunsperger PhD , Nancy Otieno MSc , Moses Masika MD , Patrick Amoth MD , Lyndah Makayotto MD , Carolyne Nasimiyu MD , Bronwyn M. Gunn PhD , Bryan Nyawanda MSc , Ouma Oluga MD , Carolyne Ngunu MD , Harriet Mirieri MPH , John Gachohi PhD , Doris Marwanga MSc , Patrick K. Munywoki PhD , Dennis Odhiambo BSc , Moshe D. Alando BSc , Robert F. Breiman MD , Omu Anzala PhD , M. Kariuki Njenga PhD , Marc Bulterys MD , Amy Herman-Roloff PhD , Eric Osoro MD , High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya, *International Journal of Infectious Diseases* (2021), doi: <https://doi.org/10.1016/j.ijid.2021.08.062>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Highlights

- Population-based cross-sectional serosurvey for SARS-CoV-2 in Nairobi, Kenya
- Over one-third of Nairobi residents had been exposed to SARS-CoV-2
- Evidence of extensive transmission similar or higher than Europe or United States
- Persons aged 20-59 years had ~2-fold higher seropositivity than those aged 0-9 years
- Infection fatality ratio >10-fold lower than that reported in Europe or United States

Journal Pre-proof

High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya

Authors

Isaac Ngere, MD^{a, b, ‡}, Jeanette Dawa, PhD^{a, b, ‡}, Elizabeth Hunsperger, PhD^c, Nancy Otieno, MSc^d, Moses Masika, MD^e, Patrick Amoth, MD^f, Lyndah Makayotto, MD^g, Carolyn Nasimiyu, MD^{a, b}, Bronwyn M. Gunn, PhD^b, Bryan Nyawanda, MSc^d, Ouma Oluga, MD^g, Carolyn Ngunu, MD^g, Harriet Mirieri, MPH^{a, b}, John Gachohi, PhD^{a, b, h}, Doris Marwanga, MSc^{a, b}, Patrick K. Munywoki, PhD^c, Dennis Odhiambo, BSc^d, Moshe D. Alando, BSc^d, Robert F. Breiman, MDⁱ, Omu Anzala, PhD^e, M. Kariuki Njenga, PhD^{a, b}, Marc Bulterys, MD^c, Amy Herman-Roloff, PhD^c, Eric Osoro, MD^{a, b, *}

Affiliations

^aWashington State University (WSU) Global Health Kenya, Nairobi, Kenya, ^bPaul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA, ^cCenter for Global Health, US Centers for Disease Control and Prevention (CDC) -Kenya, Nairobi, Kenya, ^dCenter for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya, ^eKAVI-Institute for Clinical Research, University of Nairobi, Nairobi, Kenya, ^fKenya Ministry of Health, Nairobi, Kenya, ^gDepartment of Health, Nairobi Metropolitan Services, Nairobi, Kenya, ^hSchool of Public Health, Jomo Kenyatta University of Agriculture and Technology, Kiambu, Kenya, ⁱEmory University, Atlanta USA

[‡]**Both authors contributed equally.**

*Corresponding author

Dr. Eric Osoro

Washington State University Global Health Kenya

One Padmore Place, George Padmore Road, Off Ngong Road,

Nairobi

Email: eric.osoro@wsu.edu

Telephone: +254-722216391

ABSTRACT

Background: The lower-than-expected COVID-19 morbidity and mortality in Africa has been attributed to multiple factors, including weak surveillance. We estimated the burden of SARS-CoV-2 infections eight months into the epidemic in Nairobi, Kenya.

Methods: We conducted a population-based cross-sectional survey using multi-stage random sampling to select households within Nairobi in November 2020. Sera from consenting household members were tested for antibodies to SARS-CoV-2. Seroprevalence was estimated after adjusting for population structure and test performance. Infection fatality ratios (IFRs) were calculated by comparing study estimates to reported cases and deaths.

Results: Among 1,164 individuals, the adjusted seroprevalence was 34.7% (95%CI 31.8-37.6). Half the enrolled households had at least one positive participant. Seropositivity increased in more densely populated areas (spearman's $r=0.63$; $p=0.009$). Individuals aged 20-59 years had at least 2-fold higher seropositivity than those aged 0-9 years. The IFR was 40 per 100,000 infections, with individuals ≥ 60 years old having higher IFRs.

Conclusion: Over one-third of Nairobi residents had been exposed to SARS-CoV-2 by November 2020, indicating extensive transmission. However, the IFR was >10 -fold lower than that reported in Europe and the United States, supporting the perceived lower morbidity and mortality in sub-Saharan Africa.

Key words: COVID-19 pandemic, SARS-CoV-2, seroprevalence, disease underreporting, infection underestimation

INTRODUCTION

Sixteen months after emergence of the coronavirus disease of 2019 (COVID-19), severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection had been confirmed in almost 140 million people globally and led to >2.9 million deaths (WHO, 2021a). In April 2020, the World Bank expressed concern that high virus transmission posed the greatest risk in densely populated urban areas, especially those with poor infrastructure and service delivery systems (The World Bank, 2020). In Africa, the urban population stood at 588 million people in 2020, with 50% of this population living in informal settlements, while 70% of the population were self-employed or worked in unregulated sectors, making them vulnerable to income losses and less able to adhere to COVID-19 restrictions and lockdowns (United Nations et al., 2019). These workers use overcrowded public transport systems and marketplaces, which make social distancing almost impossible (Mitlin, 2020; UNHABITAT, 2020). Yet, despite these challenges, countries within sub-Saharan Africa consistently reported lower COVID-19 cases and deaths throughout the pandemic when compared to other continents. Public health experts advanced many hypotheses to explain this outcome, ranging from poor surveillance, suboptimal testing and underreporting, to younger population, warmer and humid weather, and prior exposure to other cross-reacting coronaviruses (Njenga et al., 2020; Diop et al., 2020; Tso et al., 2021; WHO, 2020a). To address the challenge of underreporting, the World Health Organization (WHO) recommended population-based seroprevalence studies, to determine the proportion of the population that had been infected over time, and estimate important parameters such as the proportion of asymptomatic infections, infection fatality ratios, and progression towards herd immunity (WHO, 2020b).

Several COVID-19 seroprevalence studies carried out thus far in different locations reveal varying levels of underreporting, even in countries with mass testing programs for acute infections. (Lai et al., 2020; Poustchi et al., 2020; Rostami et al., 2020). Four to nine months into the pandemic, studies in multiple states in the USA and Iran found SARS-CoV-2 seroprevalence to be between 7-23%, and suggested that initially, acute infection testing, which was largely limited to symptomatic persons, underestimated total infections by >10-fold (Brown and Walensky, 2020; Poustchi et al., 2020).

The first case of COVID-19 in Kenya was reported on March 13, 2020 and by end of May 2021, the country had reported almost 171,000 cases with 3167 deaths (case fatality rate = 1.9%) with peaks in July 2020, November 2020, and March 2021 (MOH Surveillance Report No. 439, 2021). By mid-April 2020 community transmission of SARS-CoV-2 was evident in Kenya, which necessitated the closure of schools and social amenities, and cessation of movement in and out of the capital city Nairobi (Ministry of Health, Kenya, 2020). Nairobi (population 4.4. million) is one of the largest cities in East Africa and among the ten largest cities on the continent (Kenya National Bureau of Statistics, 2019a; The World Bank, 2019). By November 2020, eight months into the pandemic, Nairobi remained a hotspot for SARS-CoV-2 transmission, accounting for 46% of cases and 36% of deaths reported in Kenya (MOH Surveillance Report No. 439, 2021). To determine the level of exposure to the virus and estimate the magnitude of underreporting from government reports, we conducted a population-based seroprevalence study in Nairobi city and its suburbs (Nairobi City County) in November 2020. By the time of the study, few population-based seroprevalence studies had been conducted in Africa (Mulenga et al., 2021). Most published serosurveys from the continent were from non-representative samples such as health care workers and/or patients attending healthcare facilities or excluded children and the elderly (Abdelmoniem et al., 2021; Chibwana et al., 2020; Galanis et al., 2021; Halatoko et al., 2020; Kammon et al., 2020; Kassem et al., 2020; Kempen et al., 2020; Uyoga et al., 2021).

METHODS

Study design and eligibility

A WHO unity protocol aligned population-based cross-sectional survey, using multi-stage random sampling of households across the 17 administrative sub-counties within Nairobi City County, was conducted from November 2 to 23, 2020 (WHO, 2020c). Consenting residents, irrespective of age, in selected households, who had lived in the city for at least six months preceding the survey were enrolled. Persons with reported or documented contraindications to venipuncture were excluded.

Sample size and survey procedures

We assumed a seroprevalence of 5-8%, (Uyoga et al., 2021) relative precision of 30%, and a design effect of 1.5 to obtain a sample size of 1,216 participants. Estimating an average of 3 enrolled study participants per household, we planned to enroll 406 households at identified geospatial coordinates (geocodes) but sampled 50% more geocodes to cater for replacements households. Household selection was conducted using multi-stage random sampling. First, half of the wards in each of the 17 sub-counties were randomly selected, and then the number of households allocated to each ward was determined in proportion to its population size in the national census report (Kenya National Bureau of Statistics, 2019a). Subsequently, random geospatial coordinates (geocodes) were generated using QGIS Version 2.18.15 within each ward, corresponding to the number of allocated households (QGIS Development Team, 2009). Uninhabited areas such as the central business district, game parks, industrial parks, and restricted government compounds/institutions were excluded before generation of geocodes.

Trained study teams which included a nurse/clinician, a laboratory technologist, and a community health volunteer, used hand-held global positioning system (GPS) devices to locate households closest to the geocodes. If no one was present within the household, a revisit within 72 hours occurred before replacing the household with the next geocode within the ward, from the list of replacement geocodes. A household geocode was also replaced if the head of household declined participation of the household and there was no other consenting household near the geocode. In households where a

consenting adult was present, all eligible individuals were enrolled upon providing written consent (for adults) and parental permission and assent (for minors ≥ 12 years). Revisits to enroll household members who were not present during the first visit were scheduled within seven days.

Data and sample collection

Data were collected electronically using tablets on the REDCap© platform. Apart from the number of household residents, we collected individual data on social and demographic characteristics, medical history, presence of chronic disease, and current (time of visit), recent (last 14 days), and past (last 12 months) symptoms of respiratory illness. Respiratory illness was defined as at least two of the following symptoms: cough, running nose, sore throat, shortness of breath, chills, or fever. Chronic disease was defined as self-reported past diagnosis of hypertension, asthma, diabetes, heart disease, stroke, liver disease, kidney disease cancer, or tuberculosis. Venous blood samples were collected from each participant, transported in a cool box to Kenya Medical Research Institute (KEMRI) laboratory in Nairobi, and sera stored at -80°C before testing.

Detection of SARS-CoV-2 antibodies

Detection of total IgM and IgG antibodies was carried out using the Wantai SARS-CoV-2 two-step antigen sandwich enzyme immunoassay (EIA) kit that uses polystyrene microwell strips coated with recombinant SARS-CoV-2 antigen (Wantai Biological Pharmacy Enterprise Ltd, Beijing, China). The test has high sensitivity and specificity for anti-SARS-CoV-2 total antibodies and good correlation between detection of IgG antibodies and neutralizing antibody titers when compared with other EIA tests (GeurtsvanKessel et al., 2020; Nilsson et al., 2021; Weidner et al., 2020).

Enzyme immunoassay test validation

To validate the Wantai enzyme immunoassay test kit, we investigated whether there was cross-reactivity with antibodies to other pathogens commonly detected in patients with acute febrile illness (AFI) in sub-Saharan Africa, including malaria as suggested in other studies (Huibin Lv et al., 2020;

Njenga et al., 2020). This was conducted using blinded sera previously collected from 146 patients as follows:

- i. 37 patients with AFI, whose sera were collected before August 2019 (KEMRI protocol approval # 2980).
- ii. 20 febrile patients positive for malaria, whose sera was collected before August 2019 (KEMRI protocol approval # 2980).
- iii. 89 real-time reverse transcription-polymerase chain reaction (rRT-PCR) confirmed SARS-CoV-2 patients, hospitalized in various health facilities (Kenya National Hospital – University of Nairobi research protocol approval #P223/03/2020).

Following a series of optimization runs in our laboratory using true positives and negatives, we determined that 10 washes after addition of sera as opposed to 5 washes as recommended in the manufacturer's instructions were required. This was done to eliminate high background cross-reactivity detected with 5 washes.

All sera collected before August 2019 from malaria-positive and negative patients with AFI were negative for SARS-CoV-2 antibodies. In contrast, 79.8% (71/89) of the PCR-confirmed COVID-19 patients tested positive for SARS-CoV-2 antibodies. The sera tested from COVID-19 patients were collected at varying time points after real-time RT-PCR confirmation of SARS-CoV-2 infection, hence the possibility that some of the seronegative patients were sampled during the pre-antibody phase of infection or that the antibodies had waned if sampling was done long after the primary infection. The date of the first known positive COVID-19 test before admission/isolation was available for seven of the 18 patients whose sera tested negative for SARS-CoV-2 antibodies. For these seven patients, sera were collected a median of 6 days (range 3-51 days) after the first recorded real-time RT-PCR confirmation.

Estimating seroprevalence

The SARS-CoV-2 seroprevalence was determined in three steps. First, we summarised respondent characteristics by antibody positivity using counts and proportions and used median and interquartile ranges (IQR) for continuous variables. Second, we weighted the seroprevalence through post-stratification by raking on sex and age group to the population structure of Nairobi. The age groups applied were 0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, and 60 years and above. Finally, the weighted seroprevalence was adjusted for test characteristics as provided by the manufacturer (sensitivity of 94.4% and specificity of 100%) (Wantai Biological, 2020). The point estimates and 95% confidence interval for the unweighted, weighted and test adjusted seroprevalence estimates were reported. Household seroprevalence was defined as the proportion of households with at least one seropositive member.

We compared the adjusted sub-county seroprevalence to its population density (average number of persons per kilometer²) using Spearman's correlation and reported the coefficient values. Mixed-effects multivariable logistic regression, accounting for survey weights and clustering at household level, was conducted to determine the association between seropositivity and sex, age category, and history of respiratory illness. Adjusted odds ratio and 95% confidence intervals were reported and two-sided p-values <0.05 were considered significant. All data cleaning and analyses were done using R statistical software.

Determining level of underestimation and infection fatality ratio in Kenya

Underestimation of infections was defined as the extent to which SARS-CoV-2 infections within the Nairobi population (both symptomatic and asymptomatic) were detected by the Kenya national testing and surveillance system (Gibbons et al., 2014). Using the adjusted age-specific seroprevalence from our study, we calculated the number of infections in Nairobi as of 23 November 2020 in each age group and provided 95% confidence intervals. This was compared with the cumulative number of positive cases in Nairobi reported by the Kenya Ministry of Health (MoH) by the end of November 2020, to obtain age-specific underestimation levels. Age-specific multiplication factors were

expressed as 'n'-fold i.e., the value by which reported cases would be amplified to obtain the true number of infections.

Infection fatality ratio (IFR) was defined as the probability of death following infection. IFR was calculated by dividing the age-specific number of reported COVID-19 deaths (by the end of December 2020), by the age-specific number of infections calculated from this study and expressed as the number of deaths per 100,000 infections. This approach assumed a maximal lag of 6 weeks between infection and death, (Gibbons et al., 2014) and that a significant proportion of COVID-19 related deaths were captured by the Kenya MOH surveillance system, in large part because of heightened awareness of the pandemic, reporting requirements by WHO, and better capacity to detect severe illnesses and deaths within the capital city.

Ethics Statement

This study was reviewed and approved by the Kenya Medical Research Institute Scientific and Ethical Review Committee (number SSC 4098), National Commission for Science Technology and Innovation (number 827570), U.S. CDC (number CGH-ET-4/12/21-f3b82), and a reliance approval was provided by Washington State University Institutional Review Board based on in-country ethical reviews as provided for in the Code of Federal Regulations (45 C.F.R part 46 and 21 C.F.R. part 56). Administrative approval was provided by the Kenya MoH and Nairobi City County administration. All participants provided written consent or assent before enrollment.

RESULTS

Household and individual characteristics

Of 670 households approached, 528 (78.7%) consisting of 1,787 individuals agreed to participate in the survey. Of these 1,787 individuals, 1,186 (66.4%) consented and were enrolled, while the rest either declined participation or were unavailable during the visits. The results presented here are based on 1,164 individuals residing in 527 households whose sera were tested for SARS-CoV-2 antibodies (Figure 1).

The median age of the participants was 26 years (IQR 14-37), majority (55%) aged between 20-49 years, and 64.4% were female. Only 17 (1.5%) participants were health care workers (**Table 1**). Chronic illnesses were reported by 96 (8.2%) participants, including hypertension [45/96 (46.9%)], asthma [40/96 (41.7%)], diabetes [14/96 (14.6%)], cancer [3/96(3.1%)] and tuberculosis [3/96(3.1%)]. Forty-five percent of those with chronic illness were ≥ 60 years old, 29.5% were 50-59 years old, and 1.7% were < 20 years old. One-third of respondents reported a history of respiratory illness sometime during the year 2020 (**Table 1**).

SARS-CoV-2 seroprevalence

The crude unweighted seroprevalence was 33.0% (95% CI 30.4–35.7), that weighted for sex and age was 32.7% (95% CI 30.0–35.5), and the adjusted seroprevalence weighted for sex and age and corrected for test characteristics was 34.7% (95% CI 31.8–37.6) (**Table 2**). Participants between 20-59 years old had a seroprevalence of between 38.6% and 43.3%, which was approximately 2-fold higher than those aged 0-9 years (19.5%) (**Table 2**). Participants 60 years of age and above, had a slightly higher seroprevalence (23.5% [95% CI 10.3–43.2]) compared to the 0-9 years age group, although the difference was not statistically significant. There were no significant differences in seroprevalence by sex. Working adult participants (includes employed, self-employed, unskilled laborers, and health care workers) had a higher seroprevalence (41.7%, 95% CI 36.9-46.5) when compared to unemployed adults (35.4%, 95% CI 28.6-42.4).

On univariable analysis, participants reporting chronic diseases had higher seropositivity (39.1%, 95% CI 28.8-50.5%) compared to those without (34.3%, 95% CI 31.3-37.3%), but the difference was not statistically significant. Those reporting a history of respiratory illness during 2020 had a significantly ($p=0.043$) higher seroprevalence (39.0%, 95% CI 33.6-44.5%) compared to those who did not report a history of respiratory illness (31.8%, 95% CI 28.1-35.5%) (**Table 2**). The SARS-CoV-2 seroprevalence in 17 sub-counties of Nairobi ranged from 13.2% to 60.4%, with a median of

33.9% (IQR 25.9,42.2). The seroprevalence was higher in more densely populated sub-counties (Spearman's $r = 0.63$, $p = 0.009$) (**Figure 2**).

Adjusting for sex, history of respiratory illness, and reported chronic disease, the age groups of 10-19 years, 20-29 years, 30-39 years, 40-49 years, and 50-59 years had a nearly 2 to 3-fold higher odds of seropositivity compared to the 0-9 years age group (**Figure 3**).

Among enrolled households, 261 (49.5%) had at least one participant who tested positive for SARS-CoV-2 antibodies. Among these households, the median number of seropositive individuals per household was 1.0 (IQR 1.0-2.0; range: 1.0 to 7.0), whereas among 324 households where two or more persons were tested, 130 (40.1%) had more than one seropositive participant.

Underestimation and infection fatality ratio

The adjusted seroprevalence of 34.7% indicated that at least 1.5 million Nairobi residents may have been infected with SARS-CoV-2 since March 2020. These findings indicate the national surveillance system detected only 2.4% of all SARS-CoV-2 infections in Nairobi, reflecting an underestimation ratio of 42:1. Older age groups had lower underestimation levels, with a ratio of 17:1 for cases 50-59 years old, and 10:1 for cases ≥ 60 years old, when compared to a ratio of 101:1 for cases < 10 years old.

The estimated overall IFR associated with SARS-CoV-2 infections was 40 deaths per 100,000 infections among Nairobi residents but ranged from 1 death per 100,000 infections among 10-19 years old to 115 deaths per 100,000 infections among those ≥ 60 years old. Those ≥ 60 years old had a 28-fold higher IFR than the county average (**Table 3**).

DISCUSSION

This population-based seroprevalence study of SARS-CoV-2 is among the first to document overall and age-stratified infection levels in a populous African city (Mulenga et al., 2021; Wiens et al.,

2021). Eight months after detection of the first case in Kenya, we found SARS-CoV-2 individual seropositivity in Nairobi to be 34.7%, while approximately half of the households had at least one seropositive resident. Surprisingly, the seroprevalence observed in Nairobi was higher or in some cases comparable to those documented in countries that experienced much more severe morbidity and mortality from COVID-19 at a similar stage of the pandemic (Bajema et al., 2020; Lai et al., 2020).

In a few cities that conducted population-based COVID-19 serosurveys 6 to 9 months after the first reported case, antibody prevalence ranged between 5-23% (Bajema et al., 2020; Lai et al., 2020; Pollán et al., 2020; Poustchi et al., 2020). In Africa, few population-based seroprevalence studies have been published (Kleynhans et al., 2021; Mulenga et al., 2021; Wiens et al., 2021), while most published studies from the early phase of the pandemic are from non-representative samples such as blood donors, health care workers and patients attending health facilities (Adetifa et al., 2021; Chibwana et al., 2020; Kempen et al., 2020; Ndaye et al., 2021; NICD, 2020; Shaw et al., 2021; Uyoga et al., 2021). A study among >9,000 blood donors in Kenya estimated that SARS-CoV-2 seroprevalence was 22.7% in Nairobi by the end of September 2020 (Adetifa et al., 2021). This study was limited to recruitment of healthy individuals 15-64 years of age and relied on detection of IgG rather than total Ig. Given that the sample collection period coincided with the first epidemiologic peak in the country, the investigators may have slightly underestimated SARS-CoV-2 exposure in the country by failing to detect IgM. Similarly, a population-based study conducted earlier on in the pandemic in six districts in Zambia in July 2020 and designed to detect SARS-CoV-2 IgG in the population reported a much lower seroprevalence of 2.1%. However, when antibody testing was combined with PCR testing, SARS-CoV-2 population prevalence in Zambia increased to 10.6% (95% CI 7.3–13.9) (Mulenga et al., 2021). In Juba, South Sudan, researchers detected significant SARS-CoV-2 IgG titres in a third of residents by August 2020, suggesting that the Ministry of Health detected less than 1% of all SARS-CoV-2 infections in the country. In South Africa, 5-9% of rural residents and 23-31% of urban residents had detectable SARS-CoV-2 antibodies by November – December 2020, and it was estimated that the surveillance system only detected 5% of all SARS-CoV-2 infections (Kleynhans et al., 2021). The high prevalence of SARS-CoV-2 infections in

Nairobi, Juba, South Africa, and Zambia suggests that the widely held perception that the pandemic was less severe in Africa was likely not the result of lower virus transmission. Instead, our findings suggest that >40-fold underestimation of cases by the national surveillance system, and lower morbidity and mortality in the relatively younger African population may be the primary contributing factors to the perceived lower severity of the pandemic in the continent (Diop et al., 2020; Maeda and Nkengasong, 2021; Njenga et al., 2020; Tso et al., 2021)

Overall, the Kenya national surveillance system detected 1 case for every 42 SARS-CoV-2 infections (2.4%) in Nairobi, a number that decreased to less than 1 for every 100-190 infections among individuals <20 years old, who constitute most of the population in the country (median age of 20 years) (Kenya National Bureau of Statistics, 2019b). This suggests that mitigation measures the government implemented such as isolation of known positive cases probably had minimal effectiveness in slowing the pandemic, in part because most of the infections were likely mild or asymptomatic and thus not detected by preferential testing for symptomatic cases. This was further compounded by low turn-out for testing attributed to low health care utilization in Kenyan urban communities as has been shown in previous studies (Otieno et al., 2020).

The estimated IFR in this study (40 deaths per 100,000 infections) was at least 10 times lower than previous estimates for East Africa and 20-25 times lower than Europe or United States (Ghisolfi et al., 2020). These findings suggest that despite high SARS-CoV-2 transmission, Kenya's youthful population may have contributed to lower rates of severe COVID-19 (Kenya National Bureau of Statistics, 2019b). An important finding was that our estimated IFR for individuals ≥ 60 years old was >28-fold higher than the average IFR for other age groups and was twice as high as the estimated COVID-19 IFR for East Africa, suggesting that the elderly population may be more severely affected than previously thought and underscoring the urgent need for vaccination in this group (Ghisolfi et al., 2020). The other possible factors that may contribute to the low morbidity and mortality of COVID-19 in Africa, including the presence of cross-reacting antibodies to other coronaviruses have not been adequately investigated (Diop et al., 2020; Njenga et al., 2020; Tso et al., 2021).

The population included in this survey represented a broad range of demographics and socioeconomic statuses, including residents in affluent less densely populated sub-counties and residents in crowded sub-counties largely composed of informal settlements. We observed higher seroprevalence in more densely populated areas which likely lack improved sanitation facilities and basic infrastructure, suggesting higher transmission associated with challenges in applying mitigation measures such as social distancing and good hygiene practices. Our data suggest lower than expected transmission within households. In seropositive households where more than one household member had been tested, only 40% of households had more than one seropositive household member. Although SARS-CoV-2 transmission is higher in indoor settings as compared to outdoor settings (Bulfone Tc et al., 2021), household secondary attack rates are estimated to be only 16.6% (Madewell et al., 2020), in keeping with our findings of what appeared to be low transmission within households.

This study had several limitations. A few studies have reported loss of SARS-CoV-2 antibodies in previously seropositive individuals, perhaps associated with a weak immunologic response or low infecting viral load (Dobi et al., 2020). While we used a validated total antibody test kit, asymptomatic and mild cases that occur more commonly in younger individuals have been shown to evoke lower titers of antibodies which may be missed by EIA tests, such as that used in this study. We also may have missed acutely infected individuals who had not yet developed IgM or IgG antiviral antibodies. These limitations would bias towards underestimating population prevalence. Conversely, cross-reactivity from pre-existing antibodies may have resulted in false positives and higher seroprevalence estimates. Although we did not assess the ELISA assay used in our study for cross-reactivity, an evaluation of COVID-19 serological assays reported specificity of 99% for the Wantai SARS-CoV-2 total Ig assay we used, and therefore, the number of false-positives was likely minimal (GeurtsvanKessel et al., 2020; Lassauniere et al., 2020). Our study approach may have included fewer individuals who spent most of the daytime hours at work, thus introducing selection bias, particularly if such individuals were at higher risk of exposure. Due to a nighttime curfew, participant enrollment could not take place past the evening hours. One-fifth of the households approached declined

participation which could lead to bias if the households had characteristics related to SARS-CoV-2 exposure that were different from those households that were enrolled. We used the total population size for each ward to determine the number of households to be sampled from each sub-county. It is possible that the use of ward population rather than the number and size of households per ward to determine the number of households to be enrolled per ward/sub-county may have resulted in differences in the likelihood of an individual being selected for the study, particularly if there were significant differences in household size across sub-counties. However, we determined this risk to be minimal as there is little difference in average household size between sub-counties in Nairobi. In determining presence of respiratory illness, we used a broad definition of respiratory illness that did not include loss of taste or smell which could have led to an underestimation of COVID-19 like illness. Finally, although we assumed detection of COVID-19 related deaths among deceased individuals in Nairobi was adequately captured by the surveillance system, a postmortem study conducted in Lusaka, Zambia observed that only 6 of 70 COVID-19 related deaths identified between June and September 2020 had been tested for SARS-CoV-2 before death and up to three-quarters of all COVID-19 related deaths occurred in the community where none had been tested for SARS-CoV-2 before death (Mwananyanda et al., 2021). Similarly, the WHO and other studies estimate that global COVID-19 deaths are underreported by a factor of between 1.1-1.7 even in countries with the best mortality surveillance systems (IHME, 2021; WHO, 2021b). We should therefore interpret with caution the low IFRs described in our study which probably represents floor estimates, as we cannot confidently determine the magnitude of underreporting of COVID-19 related deaths (Tembo et al., 2021).

In conclusion, this study demonstrates extensive SARS-CoV-2 transmission in Nairobi during the first eight months of the pandemic, resulting in more than a third of residents and half of the identified households being exposed to the virus. There was significant underreporting of infections by the national surveillance system and a lower-than-expected mortality rate, attributed in part to the youthful Kenyan population.

ACKNOWLEDGEMENTS

We thank the Kenya Ministry of Health (MOH), Nairobi City County, and Nairobi Metropolitan Services for granting permission and actively participating in public sensitization for the study. We acknowledge the Kenya Medical Research Institute (KEMRI) which provided ethical approval, oversight, and field staff that carried out household visits. We would also like to thank the Washington State University Global Health Kenya research and administration staff that supported the project. We would like to thank Patrick Mwaura (KAVI-Institute of Clinical Research, University of Nairobi, Kenya) and Ruth Njoroge (Washington State University Global Health Kenya) for their technical support.

Disclaimer: The findings and conclusions in this study are those of the authors and do not necessarily represent the official position of the US NIH, KEMRI, Kenya MOH, or US Centers for Disease Control and Prevention.

Author contributions

Conceptualization: IN, JD, NO, PA, LM, CNW, BN, OO, CN, MKN, EO. Data curation: DM, EO. Formal analysis: IN, JD, BN, DM, MKN, EO. Funding acquisition: EH, MKN, MB, AHR, EO. Investigation: IN, JD, EH, NO, MM, CN, HM, DM, DO, MDA, EO. Methodology: IN, JD, NO, PA, LM, CNW, BG, BN, OO, CN, HM, DM, OA, MKN, EO. Project administration: IN, JD, HM, EO. Resources: EH, MM, OA, MKN, MB, AHR, EO. Software: DM. Supervision: IN, JD, PA, LM, CNW, OO, CN, OA, MKN, EO. Validation: IN, JD, MM, BG, JG, MKN, EO. Visualization: IN, JD, CNW, JG, DM, MKN. Writing – original draft: IN, JD, CNW, DM, RB, JG, MKN, EO. All authors reviewed and edited the manuscript.

Competing interests: The authors declare that they have no competing interests

Funding: Funding was provided by the US National Institutes of Health (NIH), grant number U01AI151799, through the Centre for Research in Emerging Infectious Diseases – East and Central Africa (CREID-ECA).

Role of the funding source

The funder did not play any role in the study design, collection, analysis and interpretation of data, manuscript writing or the decision to submit the paper for publication.

Ethics approval and consent to participate

This study was reviewed and approved by the Kenya Medical Research Institute Scientific and Ethical Review Committee (number SSC 4098), National Commission for Science Technology and Innovation (number 827570), U.S. CDC (number CGH-ET-4/12/21-f3b82), and a reliance approval provided by Washington State University Institutional Review Board. All participants provided written consent or assent before enrollment.

REFERENCES

1. Abdelmoniem R, Fouad R, Shawky S, Amer K, Elnagdy T, Hassan WA, et al. SARS-CoV-2 infection among asymptomatic healthcare workers of the emergency department in a tertiary care facility. *J Clin Virol* 2021;134:104710. <https://doi.org/10.1016/j.jcv.2020.104710>.
2. Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, et al. Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. *Nat Commun* 2021;12:3966. <https://doi.org/10.1038/s41467-021-24062-3>.
3. Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern Med* 2020. <https://doi.org/10.1001/jamainternmed.2020.7976>.
4. Brown TS, Walensky RP. Serosurveillance and the COVID-19 Epidemic in the US: Undetected, Uncertain, and Out of Control. *JAMA* 2020;324:749–51. <https://doi.org/10.1001/jama.2020.14017>.
5. Bulfone Tc, Malekinejad M, Rutherford Gw, Razani N. Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses: A Systematic Review. *J Infect Dis* 2021;223. <https://doi.org/10.1093/infdis/jiaa742>.
6. Chibwana MG, Jere KC, Kamn'gona R, Mandolo J, Katunga-Phiri V, Tembo D, et al. High SARS-CoV-2 seroprevalence in health care workers but relatively low numbers of deaths in urban Malawi. *MedRxiv* 2020. <https://doi.org/10.1101/2020.07.30.20164970>.
7. Diop BZ, Ngom M, Biyong CP, Biyong JNP. The relatively young and rural population may limit the spread and severity of COVID-19 in Africa: a modelling study. *BMJ Glob Health* 2020;5:e002699. <https://doi.org/10.1136/bmjgh-2020-002699>.
8. Dobi A, Sandenon Seteyen A-L, Lalarizo Rakoto M, Lebeau G, Vagner D, Frumence É, et al. Serological Surveillance of COVID-19 Hospitalized Patients in Réunion Island (France) Revealed that Specific Immunoglobulin G Are Rapidly Vanishing in Severe Cases. *J Clin Med* 2020;9. <https://doi.org/10.3390/jcm9123847>.
9. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. *J Hosp Infect* 2021;108:120–34. <https://doi.org/10.1016/j.jhin.2020.11.008>.
10. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. *Nat Commun* 2020;11:1–5. <https://doi.org/10.1038/s41467-020-17317-y>.
11. Ghisolfi S, Almås I, Sandefur JC, von Carnap T, Heitner J, Bold T. Predicted COVID-19 fatality rates based on age, sex, comorbidities and health system capacity. *BMJ Glob Health* 2020;5:e003094. <https://doi.org/10.1136/bmjgh-2020-003094>.
12. Gibbons CL, Mangen M-JJ, Plass D, Havelaar AH, Brooke RJ, Kramarz P, et al. Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods. *BMC Public Health* 2014;14:147. <https://doi.org/10.1186/1471-2458-14-147>.
13. Halatoko WA, Konu YR, Gbeasor-Komlanvi FA, Sadio AJ, Tchankoni MK, Komlanvi KS, et al. Prevalence of SARS-CoV-2 among high-risk populations in Lomé (Togo) in 2020. *PLOS ONE* 2020;15:e0242124. <https://doi.org/10.1371/journal.pone.0242124>.
14. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. *JAMA Intern Med* 2020;180:1576. <https://doi.org/10.1001/jamainternmed.2020.4130>.
15. Huibin Lv, Nicholas C. Wu, Owen Tak-Yin Tsang, Meng Yuan, Ranawaka A.P.M. Perera, Wai Shing Leung, et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. *Cell Rep* 2020;31:107725. <https://doi.org/10.1016/j.celrep.2020.107725>.
16. IHME. Estimation of total mortality due to COVID-19. *Inst Health Metr Eval* 2021. <http://www.healthdata.org/special-analysis/estimation-excess-mortality-due-covid-19-and-scalars-reported-covid-19-deaths> (accessed June 18, 2021).
17. Kammon AM, El-Arabi AA, Erhouma EA, Mehemed TM, Mohamed OA. Seroprevalence of antibodies against SARS-CoV-2 among public community and health-care workers in Alzintan City of Libya. *MedRxiv* 2020.

18. Kassem AM, Talaat H, Shawky S, Fouad R, Amer K, Elnagdy T, et al. SARS-CoV-2 infection among healthcare workers of a gastroenterological service in a tertiary care facility. *Arab J Gastroenterol* 2020;21:151–5. <https://doi.org/10.1016/j.ajg.2020.07.005>.
19. Kempen JH, Abashawl A, Suga HK, Difabachew MN, Kempen CJ, Debele MT, et al. SARS-CoV-2 Serosurvey in Addis Ababa, Ethiopia. *Am J Trop Med Hyg* 2020;103:2022–3. <https://doi.org/10.4269/ajtmh.20-0816>.
20. Kenya National Bureau of Statistics. 2019 Kenya population and housing census Volume I. Nairobi: Kenya National Bureau of Statistics; 2019a.
21. Kenya National Bureau of Statistics. 2019 Kenya population and housing census Volume III. Nairobi: Kenya National Bureau of Statistics; 2019b.
22. Kleynhans J, Tempia S, Wolter N, Gottberg A von, Bhiman JN, Buys A, et al. Longitudinal SARS-CoV-2 seroprevalence in a rural and urban community household cohort in South Africa, during the first and second waves July 2020-March 2021. *MedRxiv* 2021:2021.05.26.21257849. <https://doi.org/10.1101/2021.05.26.21257849>.
23. Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. *Int J Infect Dis* 2020;101:314–22. <https://doi.org/10.1016/j.ijid.2020.10.011>.
24. Lassauniere R, Frische A, Harboe ZB, Formsgaard A, Krogseth KA, Jorgensen CS. Evaluation of nine commercial SARS-CoV-2 immunoassays | medRxiv 2020. <https://www.medrxiv.org/content/10.1101/2020.04.09.20056325v1>? (accessed March 24, 2021).
25. Madewell ZJ, Yang Y, Longini IM, Halloran ME, Dean NE. Household Transmission of SARS-CoV-2. *JAMA Netw Open* 2020;3. <https://doi.org/10.1001/jamanetworkopen.2020.31756>.
26. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. *Science* 2021;371:27–8. <https://doi.org/10.1126/science.abf8832>.
27. Ministry of Health, Kenya. Govt announces extra measures to prevent spread of coronavirus Nairobi, Monday April 6, 2020 – MINISTRY OF HEALTH 2020. <https://www.health.go.ke/govt-announces-extra-measures-to-prevent-spread-of-coronavirus-nairobi-monday-april-6-2020/> (accessed January 16, 2021).
28. Mitlin D. Dealing with COVID-19 in the towns and cities of the global South. *Int Inst Environ Dev* 2020. <https://www.iied.org/dealing-covid-19-towns-cities-global-south> (accessed March 24, 2021).
29. MOH Surveillance Report No. 439. Kenya COVID-19 Situation Report No. 439 May 31st 2021 2021.
30. Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwringwa M, Yingst S, et al. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. *Lancet Glob Health* 2021. [https://doi.org/10.1016/S2214-109X\(21\)00053-X](https://doi.org/10.1016/S2214-109X(21)00053-X).
31. Mwananyanda L, Gill CJ, MacLeod W, Kwenda G, Pieciak R, Mupila Z, et al. Covid-19 deaths in Africa: prospective systematic postmortem surveillance study. *BMJ* 2021;372. <https://doi.org/10.1136/bmj.n334>.
32. Ndaye AN, Hoxha A, Madinga J, Mariën J, Peeters M, Leendertz FH, et al. Challenges in interpreting SARS-CoV-2 serological results in African countries. *Lancet Glob Health* 2021;9:e589. [https://doi.org/10.1016/S2214-109X\(21\)00060-7](https://doi.org/10.1016/S2214-109X(21)00060-7).
33. NICD. COVID-19 Special Public Health Surveillance Bulletin Issue 5 2020. https://www.nicd.ac.za/wp-content/uploads/2020/09/COVID-19-Special-Public-Health-Surveillance-Bulletin_Issue-5.pdf (accessed April 8, 2021).
34. Nilsson AC, Holm DK, Justesen US, Gorm-Jensen T, Andersen NS, Øvrehus A, et al. Comparison of six commercially available SARS-CoV-2 antibody assays—Choice of assay depends on intended use. *Int J Infect Dis* 2021;103:381–8. <https://doi.org/10.1016/j.ijid.2020.12.017>.
35. Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M, et al. Why is There Low Morbidity and Mortality of COVID-19 in Africa? *Am J Trop Med Hyg* 2020;103:564–9. <https://doi.org/10.4269/ajtmh.20-0474>.

36. Otieno PO, Wambiya EOA, Mohamed SM, Mutua MK, Kibe PM, Mwangi B, et al. Access to primary healthcare services and associated factors in urban slums in Nairobi-Kenya. *BMC Public Health* 2020;20. <https://doi.org/10.1186/s12889-020-09106-5>.
37. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet* 2020;396:535–44. [https://doi.org/10.1016/S0140-6736\(20\)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5).
38. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. *Lancet Infect Dis* 2020;21:473–81. [https://doi.org/10.1016/S1473-3099\(20\)30858-6](https://doi.org/10.1016/S1473-3099(20)30858-6).
39. QGIS Development Team. QGIS Geographic Information System 2009. <http://qgis.org> (accessed January 30, 2019).
40. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. *Clin Microbiol Infect* 2020. <https://doi.org/10.1016/j.cmi.2020.10.020>.
41. Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, et al. Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. *PLoS ONE* 2021;16. <https://doi.org/10.1371/journal.pone.0247852>.
42. Tembo J, Maluzi K, Egbe F, Bates M. Covid-19 in Africa. *BMJ* 2021;372. <https://doi.org/10.1136/bmj.n457>.
43. The World Bank. Urban and Disaster Risk Management Responses to COVID-19 2020. <http://pubdocs.worldbank.org/en/575581589235414090/World-Bank-Urban-DRM-COVID-19-Responses.pdf> (accessed March 24, 2021).
44. The World Bank. Air transport, passengers carried | Data 2019. <https://data.worldbank.org/indicator/IS.AIR.PSGR?view=map> (accessed March 24, 2021).
45. Tso FY, Lidenge SJ, Peña PB, Clegg AA, Ngowi JR, Mwaiselage J, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. *Int J Infect Dis* 2021;102:577–83. <https://doi.org/10.1016/j.ijid.2020.10.104>.
46. UNHABITAT. COVID-19 in African Cities- Impacts, Responses and Policies Recommendations 2020. https://unhabitat.org/sites/default/files/2020/06/covid-19_in_african_cities_impacts_responses_and_policies2.pdf (accessed March 24, 2021).
47. United Nations, Department of Economic and Social Affairs, Population Division. World urbanization prospects: the 2018 revision. 2019.
48. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. *Science* 2021;371:79–82. <https://doi.org/10.1126/science.abe1916>.
49. Wantai Biological. Emergency Use Authorization. Wantai SARS-CoV-2 Ab ELISA. ELISA for Total Antibody to SARS-CoV-2 2020. <https://www.fda.gov/media/140929/download> (accessed April 8, 2021).
50. Weidner L, Gänsdorfer S, Unterweger S, Weseslindtner L, Drexler C, Farcet M, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays. *J Clin Virol* 2020;129:104540. <https://doi.org/10.1016/j.jcv.2020.104540>.
51. WHO. WHO Coronavirus (COVID-19) Dashboard 2021a. <https://covid19.who.int> (accessed April 6, 2021).
52. WHO. The true death toll of COVID-19: estimating global excess mortality 2021b. <https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality> (accessed June 18, 2021).
53. WHO. Critical preparedness, readiness and response actions for COVID-19 2020a. <https://www.who.int/publications-detail-redirect/critical-preparedness-readiness-and-response-actions-for-covid-19> (accessed January 16, 2021).
54. WHO. Serology in the context of COVID-19 2020b. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/serology-in-the-context-of-covid-19> (accessed March 24, 2021).

55. WHO. Unity Studies: Early Investigation Protocols 2020c.
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations> (accessed April 16, 2021).
56. Wiens KE, Mawien PN, Rumunu J, Slater D, Jones FK, Moheed S, et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020 - Volume 27, Number 6—June 2021 - Emerging Infectious Diseases journal - CDC 2021.
<https://doi.org/10.3201/eid2706.210568>.

Journal Pre-proof

Table 1. Baseline characteristics of SARS-CoV-2 serosurvey participants in Nairobi city county, November 2020

Characteristics	Total sample (N = 1164)	
	Number	(%)
Sex	1,164	
	Female	750 (64.4%)
	Male	414 (35.6%)
Age group in years	1,164	
	0-9	179 (15.4%)
	10-19	244 (21.0%)
	20-29	265 (22.8%)
	30-39	241 (20.7%)
	40-49	134 (11.5%)
	50-59	61 (5.2%)
	60+	40 (3.4%)
Subcounty	1163*	
	Embakasi North	105 (9.0%)
	Makadara	103 (8.9%)
	Embakasi East	98 (8.4%)
	Embakasi Central	89 (7.7%)
	Kibra	83 (7.1%)
	Kasarani	80 (6.9%)
	Ruaraka	76 (6.5%)
	Dagoretti North	73 (6.3%)
	Kamkunji	71 (6.1%)
	Mathare	67 (5.8%)
	Dagoretti South	61 (5.2%)
	Roysambu	59 (5.1%)
	Embakasi South	45 (3.9%)
	Westlands	44 (3.8%)
	Embakasi West	42 (3.6%)
	Langata	39 (3.4%)
	Starehe	28 (2.4%)

Highest completed education level among adults enrolled		769*	
	No formal education		40 (5.2%)
	Primary education		247 (32%)
	Secondary education		268 (35%)
	Tertiary education		214 (28%)
Occupation		1151*	
	Less than 18 years of age		383 (33.3%)
	Employed/Self Employed		284 (24.7%)
	Unemployed		236 (20.5%)
	Unskilled labour		167 (14.5%)
	Student		64 (5.6%)
	Health care worker		17 (1.5%)
Presence of comorbidities		1,164	96 (8.2%)
Respiratory illness			
	Individuals with acute respiratory illness at time of study visit	1158*	54 (4.7%)
	Individuals with acute respiratory illness in last 2 weeks	1158*	136 (11.7%)
	Individuals with acute respiratory illness in past year	1006*	349 (34.7%)
	Individuals with acute respiratory illness among their household members at the time of study visit	1163*	112 (9.6%)

*Variable had missing values

Table 2. Seroprevalence of SARS-CoV-2 antibodies among Nairobi city county residents, November 2020

Characteristics	Total				
	sample size	Seropositive individuals	Unweighted seroprevalence ^a (95% CI)	Weighted seroprevalence ^b (95% CI)	Adjusted seroprevalence ^c (95% CI)
Overall	1,164	384	33.0% (30.4–35.7)	32.7% (30.1–35.5)	34.7% (31.8–37.6)
Sex					
Female	750	247	32.9% (29.6–36.3)	33.3% (29.5–37.1)	35.3% (31.2–39.3)
Male	414	137	33.1% (28.6–37.6)	32.0% (28.2–35.9)	34.0% (30.0–38.1)
Age group in years					
0-9	179	34	19.0% (13.2–24.7)	18.5% (13.7–23.3)	19.5% (14.6–24.7)
10-19	244	74	30.3% (24.6–36.1)	31.6% (25.0–38.2)	33.4% (26.6–40.3)
20-29	265	100	37.7% (31.9–43.6)	37.1% (31.7–42.5)	39.4% (33.8–45.3)
30-39	241	95	39.4% (33.2–45.6)	40.8% (34.4–47.3)	43.3% (36.4–50.1)
40-49	134	51	38.1% (29.8–46.3)	38.4% (29.5–47.3)	40.5% (31.2–50.3)
50-59	61	21	34.4% (22.5–46.3)	36.6% (23.2–50.0)	38.6% (25.0–53.0)
60+	40	9	22.5% (9.56–35.4)	22.6% (7.0–38.1)	23.5% (10.3–43.2)

Subcounty

			40.0% (30.6-	39.8% (30.6-	42.2% (32.7-
Embakasi North	105	42	49.4)	49.0)	52.5)
			31.1% (22.1-	33.3% (24.1-	35.2% (25.6-
Makadara	103	32	40.0)	42.5)	45)
			30.6% (21.5-	30.7% (21.7-	32.5% (23.2-
Embakasi East	98	30	39.7)	39.8)	42.3)
			27% (17.7-	26.1% (16.7-	27.7% (18.4-
Embakasi Central	89	24	36.2)	35.4)	38.5)
			44.6% (33.9-	42.8% (32.4-	45.3% (34.1-
Kibra	83	37	55.3)	53.3)	56.1)
			13.8% (6.2-	15.4% (7.3-	16.2% (8.6-
Kasarani	80	11	21.3)	23.4)	25.2)
			43.4% (32.3-	43.4% (32.2-	46.2% (34.1-
Ruaraka	76	33	54.6)	54.7)	57.3)
			38.4% (27.2-	36.6% (26.2-	38.6% (27.7-
Dagoretti North	73	28	49.5)	47.1)	49.1)
			39.4% (28.1-	34.1% (23.1-	36.1% (25.0-
Kamkunji	71	28	50.8)	45.2)	48.5)
			46.3% (34.3-	50.1% (37.7-	52.7% (39.1-
Mathare	67	31	58.2)	62.5)	65.8)
			31.1% (19.5-	31.8% (19.6-	33.9% (21.3-
Dagoretti South	61	19	42.8)	44.0)	46.3)
			13.6% (4.8-	12.5% (4.1-	13.2% (5.7-
Roysambu	59	8	22.3)	20.8)	23.4)
			28.9% (15.6-	27.1% (13.9-	28.7% (15.7-
Embakasi South	45	13	42.1)	40.3)	41.9)
			18.2% (6.8-	18.2% (6.7-	19.0% (8.5-
Westlands	44	8	29.6)	29.7)	30.9)
			57.1% (42.2-	57.3% (41.9-	60.4% (42.8-
Embakasi West	42	24	72.1)	72.7)	74.7)
Langata	39	10	25.6% (11.9-	21.9% (9.8-	23.3% (11.7-

			39.3)	34.0)	36.2)
			21.4% (6.2-	22.9% (7.0-	25.9% (11.7-
Starehe	28	6	36.6)	38.8)	46.4)

Highest completed education level among adults enrolled

			35.0% (20.2-	36.8% (20.8-	38.8% (22.3-
No formal education	40	14	49.8)	52.9)	54.5)
			36.8% (30.8-	37.2% (30.7-	39.6% (32.7-
Primary education	247	91	42.9)	43.7)	46.5)
			39.2% (33.3-	39.0% (33.2-	41.4% (35.2-
Secondary education	268	105	45.0)	44.8)	47.7)
			34.6% (28.2-	36.6% (30.3-	38.8% (32.1-
Tertiary education	214	74	41.0)	42.9)	45.7)
Missing data					

Occupation

			24.5% (20.2-	23.3% (19.2-	24.5% (20.4-
Less than 18 years of age	383	94	28.9)	27.4)	29.0)
			42.3% (36.5-	43.0% (37.2-	45.6% (39.3-
Employed/Self Employed	284	120	48.0)	48.8)	51.7)
			32.6% (26.6-	33.3% (26.9-	35.4% (28.7-
Unemployed	236	77	38.6)	39.7)	42.2)
			33.5% (26.4-	33.3% (26.2-	35.2% (27.8-
Unskilled labour	167	56	40.7)	40.4)	43.2)
			35.9% (24.2-	37.0% (25.5-	39.1% (27-
Student	64	23	47.7)	48.5)	52.2)
			35.3% (12.6-	37.6% (12.8-	38.9% (15.0-
Health care worker	17	6	58.0)	62.3)	64.3)

Presence of comorbidities

			37.5% (27.8-	36.9% (26.6-	39.1% (28.8-
Yes	96	36	47.2)	47.2)	50.5)
No	1068	348	32.6% (29.8-	32.3% (29.6-	34.3% (31.3-

				35.5)	35.2)	37.3)
Individuals with acute respiratory illness in last 2 weeks						
				33.1% (25.2-	33.1% (25.3-	35.1% (26.9-
Yes	136	45	41.0)	40.9)	43.3)	
				32.7% (29.8-	32.3% (29.4-	34.2% (31.2-
No	1022	334	35.7)	35.2)	37.3)	
Individuals with acute respiratory illness in past year						
				37.0% (31.9-	36.7% (31.6-	39% (33.6-
Yes	349	129	42.0)	41.8)	44.5)	
				30.4% (27.0-	30.0% (26.5-	31.8% (28.1-
No	657	200	34.1)	33.6)	35.5)	
Individuals with acute respiratory illness among their household members at the time of study visit						
				36.6% (27.7-	35.7% (26.9-	37.8% (28.6-
Yes	112	41	45.5)	44.5)	46.9)	
				32.6% (29.8-	32.4% (29.6-	34.3% (31.3-
No	1051	343	35.6)	35.3)	37.4)	

^aSample seroprevalence ^bSeroprevalence adjusted for county population age and sex structure ^cWeighted seroprevalence further adjusted for test performance i.e. (sensitivity and specificity)

Table 3. Estimated age specific infections, case ascertainment probabilities and infection fatality rates in Nairobi city county, November 2020

Age category	A	B	C	Proportion of infected cases reported by surveillance system (B/A x 100%)	Multiplication factor (A/B)	Estimated Infection Fatality Ratio (C/A)
	No. of estimated infections as at November 2020 from seroprevalance study Mean (95% CI)	No. of COVID cases captured by surveillance system as at 30 November 2020	No. of deaths captured by surveillance system as at 31 December 2020			
0-9	188,053 (187,883-188,224)	1,858	18	1.0%	101	0.010%
10-19	244,156 (243,979-244,333)	1,313	3	0.5%	186	0.001%
20-29	452,978 (452,744-453,211)	7,702	28	1.7%	59	0.006%
30-39	363,887 (363,684-364,091)	11,183	73	3.1%	33	0.020%
40-49	174,372 (174,228-174,516)	6,932	96	4.0%	25	0.056%
50-59	74,197 (74,103-74,291)	4,381	126	6.2%	17	0.177%
60+	27,069 (27,010-27,128)	2,812	269	12.1%	10	1.153%
Overall	1,524,886 (1,524,439-1,525,333)	36,354*	613	2.4%	42	0.040%

*Includes 173 reported cases without date of birth data

LIST OF FIGURES




Figure 1: Study enrolment flow chart for SARS-CoV-2 antibody prevalence survey in Nairobi City County, November 2020

Figure 1: Study enrolment flow chart for SARS-CoV-2 antibody prevalence survey in Nairobi City County, November 2020




Figure 2: Sub-county SARS-CoV-2 seroprevalence positivity and population density per kilometer² in Nairobi City County, November 2020




Figure 3: Multivariable mixed-effects logistic regression of factors associated with SARS-CoV-2 seropositivity, Nairobi city county. The 0-9 years group was used as the reference age category. The adjusted odds ratios for each variable are indicated as a black dot with the confidence intervals on either side.

Figure 3: Multivariable mixed-effects logistic regression of factors associated with SARS-CoV-2 seropositivity, Nairobi city county. The 0-9 years group was used as the reference age category. The adjusted odds ratios for each variable are indicated as a black dot with the confidence intervals on either side.